Nausea
5
Pipeline Programs
3
Companies
4
Clinical Trials
2
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
3
Early DiscoveryClinical DevelopmentMarket
On Market (2)
Approved therapies currently available
U
ONDANSETRONApproved
ondansetron
Unknown Companyoral2007
U
ZUPLENZApproved
ondansetron
Unknown Companyoral2010
Competitive Landscape
3 companies ranked by most advanced pipeline stage
M&
Merck & Co.RAHWAY, NJ
2 programs1
MK0869, aprepitant / Duration of Treatment: 3 daysPhase 31 trial
Development of a Predictive Model for Post-Discharge Nausea and Vomiting (PDNV)N/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
GSKOndansetron
Merck & Co.MK0869, aprepitant / Duration of Treatment: 3 days
TakedaOndansetron
Merck & Co.Development of a Predictive Model for Post-Discharge Nausea and Vomiting (PDNV)
Clinical Trials (4)
Total enrollment: 2,970 patients across 4 trials
A RCT of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting in the Emergency Department
Start: Oct 2003Est. completion: Nov 2005120 patients
Phase 4Completed
Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)
Start: Dec 2002Est. completion: Dec 2004820 patients
Phase 3Completed
Ondissolve in the Prophylaxis/Rescue of Radiation Induced Nausea and Vomiting
Start: Nov 2013Est. completion: Jun 201430 patients
Phase 2Completed
NCT00514878Merck & Co.Development of a Predictive Model for Post-Discharge Nausea and Vomiting (PDNV)
Development of a Predictive Model for Post-Discharge Nausea and Vomiting (PDNV)
Start: Aug 2007Est. completion: Nov 20082,000 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space